FDA Needs More Review Time for Adolor Thursday September 13, 8:40 am ET Adolor Says FDA Needs More Time to Review the Application for Entereg EXTON, Pa. (AP) -- Biotechnology company Adolor Corp. said Thursday the Food and Drug Administration will need more time to review the company's application for its experimental constipation treatment Entereg. The FDA requested additional information in June as part of a "approvable letter" in November. The drug is being developed with GlaxoSmithKline PLC. The companies halted studies on the drug in April after data showed patients taking the drug were more prone to benign and cancerous lesions, fractures and cardiovascular events.